NASDAQ:VIRI Virios Therapeutics (VIRI) Stock Price, News & Analysis $1.11 -0.01 (-0.89%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC Filings About Virios Therapeutics Stock (NASDAQ:VIRI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Virios Therapeutics alerts:Sign Up Key Stats Today's Range$1.11▼$1.1950-Day Range$1.03▼$2.3652-Week Range$0.13▼$1.04Volume74,653 shsAverage Volume1.05 million shsMarket Capitalization$21.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Virios Therapeutics, Inc. (NASDAQ: VIRI) is a clinical-stage biotechnology company focused on developing antiviral therapies for conditions it believes may be associated with the activation of latent herpesviruses. The company’s research has centered on the potential role of viral reactivation in chronic diseases and related inflammatory symptoms. Virios’ lead investigational product candidate has been IMC-1, a fixed-dose combination of famciclovir, an antiviral medication, and celecoxib, an anti-inflammatory drug. The company has evaluated IMC-1 as a potential treatment for fibromyalgia, a chronic disorder commonly associated with widespread pain, fatigue and other symptoms. IMC-1 is an investigational therapy and has not been approved for commercial use. The company was established in 2018 and has historically operated as a development-stage biotechnology business based in the United States. Its activities have primarily involved preclinical and clinical research, product development and potential partnerships related to antiviral treatments. Publicly available information does not establish a broad commercial geographic footprint, as Virios’ disclosed operations have focused principally on advancing its development programs rather than marketing approved products.AI Generated. May Contain Errors. Read More Receive VIRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIRI Stock News HeadlinesDogwood Therapeutics Inc (DWTX)March 16, 2025 | investing.comDogwood prices 578,950 shares at $8.26 in registered direct offeringMarch 13, 2025 | markets.businessinsider.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 14 at 1:00 AM | Profits Run (Ad)Dogwood announces conversion of existing $19.5M in debt to equityMarch 12, 2025 | markets.businessinsider.comDWTX Stock trading resumesFebruary 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. (DWTX)February 2, 2025 | finance.yahoo.comDWTX Stock trading halted, volatility trading pauseJanuary 28, 2025 | markets.businessinsider.comDWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly GrowthJanuary 23, 2025 | msn.comSee More Headlines VIRI Stock Analysis - Frequently Asked Questions How have VIRI shares performed this year? Virios Therapeutics' stock was trading at $4.16 at the start of the year. Since then, VIRI shares have decreased by 73.1% and is now trading at $1.12. How were Virios Therapeutics' earnings last quarter? Virios Therapeutics, Inc. (NASDAQ:VIRI) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. When did Virios Therapeutics IPO? Virios Therapeutics (VIRI) raised $30 million in an IPO on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Virios Therapeutics? Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virios Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Atossa Genetics (ATOS), Beyond Meat (BYND), Palantir Technologies (PLTR), SNDL (SNDL), Tiziana Life Sciences (TLSA), AMC Entertainment (AMC) and Ford Motor (F). Company Calendar Today11/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VIRI CIK1818844 Webwww.virios.com Phone866-620-8655FaxN/AEmployees5Year Founded2012Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-130.33% Return on Assets-115.00% Debt Debt-to-Equity RatioN/A Current Ratio7.27 Quick Ratio7.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book5.55Miscellaneous Outstanding Shares19,258,000Free Float16,909,000Market Cap$21.38 million OptionableNo Data Beta1.58 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:VIRI) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredLog into Keith’s $5,000 AI Signals Trading system todayA new AI system from the TradeSmith Daily team shows trades taking shape 90 minutes before they occur, with 93...TradeSmith | SponsoredJ.P. Morgan Solved the AI Power Problem in 1882J.P. Morgan solved the power problem facing American AI labs back in 1882. With Democrats taking control of Co...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
